In this perspective, the rationale for the PD-1/PD-L1 axis inhibition for adjuvant purposes is in the concept of “a high immunological memory” involved in glioma diffusion, starting from the early phases of tumorigenesis and through a number of different clues from adaptative immune system involvement [10]. This evidence concerns the gene PDCD1 and central nervous system cancer.